Yeast Infection Treatment Market Report 2024 - Yeast Infection Treatment Market Growth And Trends

"The Business Research Company recently released a comprehensive report on the Global Yeast Infection Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

According to The Business Research Company's, The yeast infection treatment market size has grown strongly in recent years. It will grow from $4.02 billion in 2023 to $4.33 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increased prevalence of yeast infections, growing awareness about fungal infections, aging population, rise in healthcare expenditure globally, and development and approval of new antifungal medications.

The yeast infection treatment market size is expected to see strong growth in the next few years. It will grow to $5.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing adoption of telemedicine for remote consultations, personalized medicine approaches for targeted treatment, emergence of combination therapies for enhanced efficacy, growing emphasis on natural and herbal remedies, and focus on microbiome-based therapies for infection management. Major trends in the forecast period include advancements in genomic research, development of compact and accurate diagnostic equipment, technological advancements in the field of yeast infection diagnosis and treatment, increasing investments in research and development, and strategic partnerships.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/yeast-infection-treatment-global-market-report

Market Drivers and Trends:
The rise in the prevalence of autoimmune disease is expected to propel the growth of the yeast infection treatment market going forward. Autoimmune disease is a condition where the immune system mistakenly attacks healthy cells, tissues, and organs, weakening bodily function and potentially becoming life-threatening. Yeast infection treatment are used in managing and preventing the complications of autoimmune disease by addressing recurrent yeast infections, which are linked to certain autoimmune syndromes, and by potentially modulating the immune response through the management of fungal infections in patients with autoimmune conditions. For instance, in March 2023, according to the National Institutes of Health, a US-based federal agency for conducting and supporting medical research, an estimated 8.4 million people globally were predicted to have type 1 diabetes (T1DM) in 2021, with 500,000 new cases reported in that year. Further, the estimated population with T1DM is expected to be between 13.5 and 17.4 million by 2040. Therefore, the rise in the prevalence of autoimmune diseases is driving the growth of the yeast infection treatment market.

Major companies operating in the yeast infection treatment market are focusing on introducing innovative solutions or medications, such as non-azole oral antifungals, to gain a competitive edge in the market. A non-azole oral antifungal is a medication taken by mouth that fights fungal infections but does not belong to the azole class of antifungals. For instance, in December 2022, SCYNEXIS, a US-based biotechnology company, announced approval from the United States Food and Drug Administration (FDA), a US-based federal agency, for the second indication for BREXAFEMME (ibrexafungerp tablets). This is an innovative non-azole oral antifungal, the first FDA-approved therapy used for both the treatment of vaginal yeast infection, also known as vulvovaginal candidiasis (VVC), and the reduction in the incidence of recurrent VVC. It offers a novel alternative with broad-spectrum activity, impacting the dynamics of the yeast infection treatment market and addressing limited options for patients with recurrent VVC. The recommended dosage of BREXAFEMME for the treatment of VVC is 300 mg (two 150 mg tablets), given one day at a time, about 12 hours apart, for a total of 600 mg (four 150 mg tablets) every day.

Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13958&type=smp

Major Key Players of the Market:
Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Thermo Fisher Scientific Inc., Abbott Laboratories, AstraZeneca PLC, Bayer AG, Astellas Pharma Inc., Torrent Pharmaceuticals, Catalent Inc., bioMérieux SA, Cipla, Bruker Corporation, Brundavan Laboratories Private Limited, Glenmark Pharmaceuticals Ltd, Zydus Lifesciences, Prestige Consumer Healthcare Inc., CordenPharma International, Synmedic Laboratories, Basilea Pharmaceutica AG, Jubilant Pharmova Limited, Curia Global Inc., Synexis LLC, Manus Aktteva Biopharma LLP

Yeast Infection Treatment Market 2024 Key Insights:
• The Major Key Players of the Market:
Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Thermo Fisher Scientific Inc., Abbott Laboratories, AstraZeneca PLC, Bayer AG, Astellas Pharma Inc., Torrent Pharmaceuticals, Catalent Inc., bioMérieux SA, Cipla, Bruker Corporation, Brundavan Laboratories Private Limited, Glenmark Pharmaceuticals Ltd, Zydus Lifesciences, Prestige Consumer Healthcare Inc., CordenPharma International, Synmedic Laboratories, Basilea Pharmaceutica AG, Jubilant Pharmova Limited, Curia Global Inc., Synexis LLC, Manus Aktteva Biopharma LLP is expected to grow toYeast Infection Treatment Market 2024 Key Insights:
• Autoimmune Disease Surge Fuels Growth In Yeast Infection Treatment Market
• Increasing Focus On Introducing Innovative Oral Antifungal Solutions To Revolutionize Yeast Infection Treatment
• North America was the largest region in the yeast infection treatment market in 2023.

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/customise?id=13958&type=smp

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

This release was published on openPR.